SXSW 2025

Meet LUUK, the first GenAI Helping End the HIV Epidemic

Description:

Join us for a groundbreaking panel discussion at SXSW featuring a unique dialogue between HIV experts and LUUK, an AI-generated advocate presented as a lifelike hologram. Developed from the insights and experiences of millions living with HIV, LUUK embodies the voice and perspective of the LGBTQ+ community. As the medical community edges closer to eradicating HIV, many still face stigma and isolation. LUUK will share his journey, the stories of those he has met, and his vision for a future free of HIV. Experience this technologically and emotionally compelling panel like never before.


Related Media

Other Resources / Information

https://x.com/ViiVHC/status/1816093607712985510
HIV Science as Art @ AIDS 2024 - https://www.linkedin.com/posts/viiv-healthcare_aids2024-activity-7221524181107023872-rZwQ/
ViiV Healthcare on LinkedIn: #aids2024
This past Sunday marked the grand opening of HIV Science as Art at #AIDS2024 in Munich, and it was a night


Takeaways

  1. Success in Therapy, But Challenges Remain: People with HIV see great success with therapies, but access and stigma are still global issues.
  2. Ending the Epidemic : ViiV and others are close to ending HIV, but we must ensure equal access and dignity for all.
  3. Meet LUUK – A Symbol of Hope LUUK, the first AI-generated human helping end the HIV epidemic.

Speakers

  • Robert Wainwright, AMD Global Innovation Director, HAVAS NOW
  • LUUK HIV ADVOCATE, World First GenAI HIV Advocate, HAVAS and VIIV
  • Maggie Czarnogorski, Head, Digital Innovation and Implementation Science at ViiV Healthcare, Viiv Healthcare
  • Javier Gómez de Quero del Castillo, MD CCO, HAVAS NOW

Organizer

Robert Wainwright, AMD, Global Innovation Director, Havas NOW


Meta Information:

  • Event: SXSW
  • Format: Panel
  • Track: Health & MedTech
  • Track 2
  • Level: Intermediate


Add Comments


SXSW reserves the right to restrict access to or availability of comments related to PanelPicker proposals that it considers objectionable.